| Literature DB >> 29095808 |
Mary Figgatt, James Hyde, David Dziewulski, Eric Wiegert, Scott Kishbaugh, Grant Zelin, Lloyd Wilson.
Abstract
Cyanobacteria, also known as blue-green algae, are photosynthetic, aquatic organisms found in fresh, brackish, and marine water around the world (1). Rapid proliferation and accumulation of potentially toxin-producing cyanobacteria characterize one type of harmful algal bloom (HAB). HABs have the potential to cause illness in humans and animals (2,3); however, the epidemiology of these illnesses has not been well characterized. Statewide in 2015, a total of 139 HABs were identified in New York, 97 (70%) of which were confirmed through laboratory analysis; 77 independent beach closures were ordered at 37 beaches on 20 different bodies of water. To better characterize HAB-associated illnesses, during June-September 2015, the New York State Department of Health (NYSDOH) implemented a pilot surveillance system in 16 New York counties. Activities included the collection of data from environmental HAB reports, illness reports, poison control centers, and syndromic surveillance, and increased outreach to the public, health care providers, and veterinarians. During June-September, 51 HAB-associated illnesses were reported, including 35 that met the CDC case definitions*; 32 of the cases occurred in humans and three in dogs. In previous years, New York never had more than 10 HAB-associated illnesses reported statewide. The pilot surveillance results from 16 counties during a 4-month period suggest that HAB-associated illnesses might be more common than previously reported.Entities:
Mesh:
Year: 2017 PMID: 29095808 PMCID: PMC5689215 DOI: 10.15585/mmwr.mm6643a5
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Illness outcomes and number of commonly reported symptoms for harmful algal bloom–associated illnesses in humans (N = 32) and dogs (N = 3),* identified through a pilot surveillance system — New York, June–September 2015
| Outcome/Symptom | No. of human cases | No. of canine cases |
|---|---|---|
|
| ||
| Outpatient care | 17 | 0 |
| Hospitalized | 0 | 2 |
|
| ||
| Skin problems (e.g., rash) | 22 | 0 |
| Respiratory (e.g., cough or dry cough) | 16 | 0 |
| Gastrointestinal (e.g., abdominal pain, diarrhea, nausea, vomiting) | 15 | 3 |
| Other symptoms (e.g., chills, muscle aches, or watery eyes) | 13 | 0 |
| Fatigue/General weakness | 11 | 2 |
| Sore throat | 11 | 0 |
| Neuroglogic (e.g., headache or seizure) | 6 | 2 |
|
| ||
| Swimming | 28 | 3 |
| Boating | 7 | 0 |
| Wading | 6 | 3 |
| Personal watercraft (e.g., kayak or canoe) | 4 | 0 |
| Tubing/Waterskiing | 2 | — |
| Jet skiing | 1 | — |
| Drinking untreated water | 0 | 3 |
* Among 32 human cases, 11 were suspected, 20 were probable, and one was confirmed. All three canine cases were probable. https://www.cdc.gov/habs/pdf/ohhabs-case-and-event-definitions-table-3-14-17.pdf.
† Includes reported visit to an emergency department, urgent care clinic, or primary care.
§ Categories are not mutually exclusive. Patients could have multiple symptoms and exposures.